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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in China in late 2019 and is now an ongoing pandemic \[[@CR1]\]. SARS-CoV-2 is known as the coronavirus, (a positive-sense single-stranded RNA, enveloped virus), and the genome size is one of the largest among RNA viruses. SARS-CoV-2 is similar to severe acute respiratory syndrome coronavirus (SARS-CoV). Previous studies have shown that the natural origin for SARS-CoV-2 is a bat \[[@CR2]--[@CR6]\]. Coronavirus disease (COVID-19) is an infectious disease ranging from a mild to more severe respiratory disease, common respiratory manifestations of COVID-19 is dry cough, fever, dyspnea, arthralgia and malaise \[[@CR2], [@CR3]\], and less common symptoms such as nausea, vomiting, diarrhea and abdominal pain \[[@CR7]\], is transmitted by person-to-person \[[@CR2], [@CR3]\]. However, in several countries such as South Korea, China, Iran and Italy reported taste and smell dysfunctions in COVID‐19 infection \[[@CR1], [@CR8]\].

SARS-CoV-2 binds directly the angiotensin converting enzyme 2 (ACE2) cell receptors such as SARS-CoV, to infect humans. Also, ACE2 receptors are detected on glial cells and neurons in the brain \[[@CR1]\]. According to current studies, alveolar epithelial cells, mucosa of oral cavity, intestine, kidney and heart express ACE2. ACE2 highly expresses in tongue than other oral cavity (buccal and gingival), and these studies show the mucosa of oral cavity is vulnerable to COVID-19 infection \[[@CR7]\]. Entrance of SARS-CoV-2 via the olfactory bulb is showed in mice model \[[@CR9]\].

Many viruses such as rhinovirus, Para influenza, Epstein--Barr virus, and some coronavirus may lead to smell and taste disorders \[[@CR9], [@CR10]\]. Permanent smell disorders are induced by viral upper respiratory tract infections \[[@CR11]\]. Current studies among patients show a relationship between COVID-19 infection and smell disorders (hyposmia, anosmia) and loss of taste (ageusia), however, olfactory disorder to be more prevalent than gustatory dysfunctions \[[@CR2], [@CR12]\]. According to some reports, patients with COVID-19 infection show an entire or little loss of taste and smell \[[@CR13]\], without rhinorrhea or nasal obstruction \[[@CR10]\].

The exact pathogenesis of SARS-CoV-2 that causes anosmia and ageusia remains unclear \[[@CR14]\], but possible reasons about anosmia could be central nervous system (CNS) involvement and nasal epithelium damaged by the microorganisms \[[@CR15]\]. These studies showed that coronavirus may infect the human CNS \[[@CR13]\] through the nose near the olfactory epithelium \[[@CR11]\] and may be neuroinvasive in humans \[[@CR8]\]. The route of entrance of the coronaviruses is via olfactory nerves or peripheral trigeminal into the CNS, so COVID-19 can damage the trigeminal and olfactory nerve and cause dysosmia and dysgeusia \[[@CR13]\], another probability of COVID-19 infection may cause to decrease the sensitivity of sensory neurons reflexes \[[@CR8]\]. According to another theory, people popularly consume chemicals and disinfectants in the ongoing pandemic that may cause smell and taste disorders \[[@CR13]\]. According to the clinical studies, post-viral anosmia is one of the reasons of smell disorders in adults and can be stable \[[@CR15]\]. Recently, a research shows that SARS‐CoV‐2 RNA was isolated in the cerebrospinal fluid that suggests the neuroinvasiveness of SARS‐CoV‐2 \[[@CR8]\]. However, there are some challenges about the smell and taste disorders in patients with COVID-19. The aim of the current review was to investigate the association of patients with COVID-19 with olfactory and gustatory dysfunctions in recent studies.
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We conducted a narrative review to determine whether SARS-CoV-2 can affect the olfactory and gustatory system. Literature search was carried out in the databases of Scopus, PubMed, ScienceDirect, UpToDate, and Web of Science using the keywords in combination on the following search strategy:A.\[Coronavirus\] OR \[COVID-19\] OR \[SARS-CoV-2\] OR \[Novel Coronavirus\] OR \[2019-nCoV\]B.\[Olfactory\] OR \[Gustatory\] OR \[Anosmia\] OR \[Parosmia\] OR \[Hyposmia\] OR \[Phantosmia\] OR \[Ageusia\] OR \[Microsmia\] OR \[Dysgeusia\] OR \[Parageusia\]C.\[A\] AND \[B\]

Inclusion criteria were as follows: language (English-written studies), type of study (original papers, abstracts, reports, reviews, letters to the editor, and clinical trials), and publication date (from December 2019 to April 2020). We excluded documents with inappropriate topics including old data that were not relevant to the main objective of the study. Also, non-English articles, ongoing manuscripts and papers addressing non-human studies, or discussing COVID-19 symptoms in general, without reference to olfactory or gustatory dysfunctions were excluded.

Finally, we screened the titles and abstracts of retrieved documents to identify studies meeting the inclusion criteria. The appropriate full-text articles were included and their results were discussed to make the final selection. After reading the full text of all eligible papers, the researchers made the final decision for each study.
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In a recent review, we studied the current evidences on olfactory and gustatory dysfunctions of COVID-19. For this purpose, 336 documents were identified and after removing duplicate articles (*n* = 134), 370 records were screened. By applying the inclusion and exclusion criteria, 346 articles were removed and finally 24 articles were reviewed in full text. Articles in the selection process are shown by the PRISMA diagram (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA diagram of articles included

In this study, we finally reviewed 24 documents including 21 articles (9 reports, 6 reviews, 5 letters to the editor, and 1 cross-sectional study) and three clinical trials. The reviewed studies were conducted in the USA (*n* = 4), UK (*n* = 4), Iran (*n* = 4), Spain (*n* = 2), Italy (*n* = 2), China (*n* = 2), France (*n* = 2), Norway (*n* = 1), Switzerland (*n* = 1), Cuba (*n* = 1) and Denmark (*n* = 1). Review of current studies has shown that anosmia, hyposmia (microsmia), ageusia and dysgeusia (parageusia) are symptoms of COVID-19 disease that occurs in some patients (Table [1](#Tab1){ref-type="table"}). According to the findings, anosmia was the most common symptom (*n* =  23) among other olfactory and gustatory manifestations of COVID-19. The frequency of identified symptoms is shown in Fig. [2](#Fig2){ref-type="fig"}. Table 1Identified olfactory/gustatory dysfunctions of COVID-19 based on the review of literatureIDFirst author (reference)Type of studyCountryOlfactory/gustatory dysfunctionsAnosmiaHyposmia (microsmia)AgeusiaDysgeusia (parageusia)Other1Russell B \[[@CR12]\]ReportUKYes--YesYes2Machado C \[[@CR2]\]ReviewCubaYesYesYesYesDyssomnia----parosmia3Villalba N \[[@CR3]\]Case reportSpainYesYes--Yes--4Ollarves--Carrero M \[[@CR16]\]Case reportSpainYesYes--YesDysosmia--hypogeusia5Troyer E \[[@CR17]\]Narrative reviewUSAYes--Yes----6Bagheri S \[[@CR15]\]Cross-sectionalIranYesYesYes--Hypogeusia7Ovesen T \[[@CR11]\]Case reportDenmarkYesYesYes----8Gane S \[[@CR18]\]Case reportUKYes--Yes----9Pérez C \[[@CR19]\]ReportUSAYesYesYesYes--10Hjelmesæth J \[[@CR20]\]Case reportNorwayYesYesYesYes--11Gautier JF \[[@CR21]\]Letter to the editorSwitzerlandYes--Yes----12Brann D \[[@CR22]\]Clinical trialsUSAYesYes------13Lechien J \[[@CR10]\]Case ControlFranceYesYesYesYesPhantosmia--parosmia14Galougahi M \[[@CR14]\]Letter to the editorIranYesYes----Hypogeusia15Hopkins C \[[@CR23]\]Clinical trialsUKYes--------16Walker A \[[@CR24]\]Clinical trialsUKYesYes----Yes--17Wu Y \[[@CR25]\]ReviewChinaYes--YesYes--18Soler Z \[[@CR26]\]ReviewUSAYesYesYes----19Li Y \[[@CR8]\]ReviewChinaYesYes------20Giacomelli A \[[@CR9]\]Letter to the editorItalyYes----YesDysosmia21Eliezer M \[[@CR27]\]Case reportFranceYes--------22Lovato A \[[@CR1]\]ReviewItalyYesYes----At least one taste or olfactory disorder23Keyhan SO \[[@CR13]\]Letter to the editorIran------YesDysosmia24Ghiasvand F ([@CR28])Letter to the editorIranYes--------Fig. 2Frequencies of COVID-19 olfactory and gustatory dysfunctions
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COVID-19 infection with common symptoms such as fever and chills, cough and shortness of breath spread rapidly around the world \[[@CR29], [@CR30]\]. As the disease progressed and many people became infected with the virus, more symptoms such as gastrointestinal involvements, neurologic complications and neuropsychiatric symptoms were reported \[[@CR17], [@CR19], [@CR31]\]. Evidences of anosmia and dysgeusia have also been published in recent days \[[@CR3], [@CR12], [@CR26]\]. Therefore, in this study, we reviewed the olfactory and gustatory dysfunctions of COVID-19.

Our review study showed that patients with COVID-19 infection may have loss of taste or smell as the symptom. Most studies (95.8%) have confirmed the symptoms of anosmia in patients with SARS-CoV-2 infection \[[@CR1]--[@CR3], [@CR8]--[@CR12], [@CR14]--[@CR28]\]. It is therefore likely that a surge in the spread of olfactory abnormalities happened during the epidemic of COVID-19 infection \[[@CR1], [@CR22]\]. Rather than injury to the structure of the receptors, the virus has been suggested to cause some kind of inflammation in the olfactory nerves \[[@CR3]\]. However, researchers\' findings suggest that the exact mechanism of olfactory and gustatory dysfunctions requires further investigation \[[@CR11], [@CR15]\].

Anosmia has been anecdotally reported as a distinct symptom in patients who have been diagnosed with COVID-19 in other studies \[[@CR2], [@CR3], [@CR12], [@CR16], [@CR17]\]. However, existing cohort studies have not highlighted these symptoms, and the frequency and effectiveness of COVID-19 for these symptoms is not yet conclusive \[[@CR3], [@CR9]\]. The findings of Ghiasvand et al.'s study have implied that anosmia is a new symptom of COVID-19 infection and more research is needed to find how the virus affects patients\' olfactory system \[[@CR28]\].

Anosmia is particularly seen in patients positive for the coronavirus who do not have any other clinical symptoms \[[@CR3]\]. Gane et al., in a case report study, have reported a patient presenting with isolated sudden onset anosmia (ISOA) who went on to test positive for COVID-19 infection and did not develop any further symptoms such as respiratory or gastrointestinal symptoms that other patients may have \[[@CR18]\]. Similarly, Eliezer et al. showed that the association of a sudden and complete olfactory function loss, without nasal obstruction in a patient with other symptoms, such as cough or fever, should alert the clinician to suspect SARS-CoV-2 infection \[[@CR27]\]

Review of current studies showed that, in addition of anosmia, evidences of ageusia and dysgeusia (parageusia) were also seen in patients with COVID-19 \[[@CR2], [@CR10], [@CR19], [@CR20], [@CR25]\]. The possibility that SARS-CoV-2 might cause olfactory and gustatory dysfunctions is certainly acceptable \[[@CR26]\]. Current studies indicated that hyposmia or anosmia and dysgeusia may be an early symptom associated with the COVID-19 infection \[[@CR12], [@CR19], [@CR25]\].

A growing number of patients with SARS-CoV-2 infection report a sudden loss of smell or taste functions. It seems that anosmia and dysgeusia might be observed in COVID-19 patients \[[@CR25]\]. Based on a case control study results, the COVID-19-infected patients may just present olfactory and gustatory dysfunctions without other significant symptoms. The only anosmia or ageusia symptom needs to be recognized by the infectious diseases specialists as an important symptom of the SARS-CoV-2 infection \[[@CR10]\].

Other similar studies have confirmed the above-mentioned clinical manifestations \[[@CR1], [@CR2], [@CR20]\]; for example, Machado in a review study concluded that because the existence of a relationship between post-infectious manifestations and COVID-19 is likely, it is highly recommended that those patients who experience complications such as smell and/or taste loss, even as only symptoms, should be considered as potential SARS-CoV-2 infection carriers \[[@CR2]\]. Moreover, Hjelmesæth et al., in a case report study have concluded that patients with SARS-CoV-2 infection may have loss of taste or smell as the only symptom \[[@CR20]\].
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Although there have been few reports of definite change in smell and taste perception in patients with COVID-19, the findings of these studies raise the question whether SARS-CoV-2 may cause olfactory and gustatory dysfunctions \[[@CR2], [@CR13], [@CR21], [@CR22]\]. The results of our study support recent reports that SARS-CoV-2 may infect oral and nasal tissues and cause olfactory and gustatory dysfunctions. These findings may aid future research on the diagnosis, prevention and treatment of COVID-19 consequences.
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